Patents by Inventor Thomas Luger

Thomas Luger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CNS
    Publication number: 20200360484
    Abstract: The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: November 19, 2020
    Inventors: THOMAS LUGER, KARIN LOSER, SVEN MEUTH
  • NDP-MSH for treatment of inflammatory and/or neurodegenerative disorders of the central nervous system
    Patent number: 10610573
    Abstract: The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 7, 2020
    Assignee: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
    Inventors: Thomas A Luger, Karin Loser
  • Inflammation inhibiting compounds
    Patent number: 10046020
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 14, 2018
    Inventor: Thomas Luger
  • Inflammation Inhibiting Compounds
    Publication number: 20170087202
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Application
    Filed: December 14, 2016
    Publication date: March 30, 2017
    Inventor: Thomas LUGER
  • Inflammation inhibiting compounds
    Patent number: 9550807
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 24, 2017
    Inventor: Thomas Luger
  • NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
    Publication number: 20160158322
    Abstract: The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 5, 2014
    Publication date: June 9, 2016
    Inventors: Thomas A. LUGER, Karin LOSER
  • Inflammation Inhibiting Compounds
    Publication number: 20150087578
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 26, 2015
    Inventor: Thomas LUGER
  • Inflammation inhibiting compounds
    Patent number: 8846617
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: July 16, 2011
    Date of Patent: September 30, 2014
    Inventor: Thomas Luger
  • Inflammation Inhibiting Compounds
    Publication number: 20120045462
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Application
    Filed: July 16, 2011
    Publication date: February 23, 2012
    Inventor: Thomas LUGER
  • Inflammation-inhibiting compounds
    Patent number: 8003608
    Abstract: The present invention relates to the use of a compound of the formula Lys-X where X is a hydroxyl group, an amino group, alkoxy, Pro or Pro-Thr, or of a pharmaceutically acceptable salt thereof, for the treatment of inflammations. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 23, 2011
    Inventor: Thomas Luger
  • Inflammation-inhibiting compounds
    Publication number: 20040077552
    Abstract: The present invention relates to the use of a compound of the formula Lys-X where X is a hydroxyl group, an amino group, alkoxy, Pro or Pro-Thor, or of a pharmaceutically acceptable salt thereof, for the treatment of inflammations. The invention also relates to the use of &agr;MSH for inducing tolerance.
    Type: Application
    Filed: September 26, 2003
    Publication date: April 22, 2004
    Inventor: Thomas Luger